Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio di fase III, in aperto, su Dato-DXd di prima linea in combinazione con Rilvegostomig per il NSCLC avanzato non squamoso con elevata espressione di PD-L1 (TC ≥ 50%) e senza alterazioni genomiche utilizzabili (TROPION-Lung10)

27 ottobre 2026 aggiornato da: AstraZeneca

Uno studio globale di Fase III, randomizzato, in aperto, su Datopotamab Deruxtecan (Dato-DXd) in combinazione con Rilvegostomig o Rilvegostomig in monoterapia rispetto a Pembrolizumab in monoterapia per il trattamento di prima linea di partecipanti con NSCLC non squamoso localmente avanzato o metastatico con elevata Espressione PD-L1 (TC ≥ 50%) e senza alterazioni genomiche utilizzabili (TROPION-Lung10)

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Panoramica dello studio

Descrizione dettagliata

This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy compared with Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Tipo di studio

Interventistico

Iscrizione (Stimato)

675

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Birtinya, Australia, 4575
        • Ritirato
        • Research Site
      • Blacktown, Australia, 2148
        • Ritirato
        • Research Site
      • Clayton, Australia, 3168
        • Reclutamento
        • Research Site
      • Gosford, Australia, 2250
        • Reclutamento
        • Research Site
      • Melbourne, Australia, 3000
        • Ritirato
        • Research Site
      • South Brisbane, Australia, QL 4101
        • Reclutamento
        • Research Site
      • Wodonga, Australia, 3690
        • Reclutamento
        • Research Site
      • Innsbruck, Austria, 6020
        • Reclutamento
        • Research Site
      • Krems, Austria, 3500
        • Reclutamento
        • Research Site
      • Linz, Austria, 4020
        • Reclutamento
        • Research Site
      • Rankweil, Austria, 6830
        • Reclutamento
        • Research Site
      • Vienna, Austria, 1210
        • Reclutamento
        • Research Site
      • Vienna, Austria, 1140
        • Reclutamento
        • Research Site
      • Wels, Austria, 4600
        • Ritirato
        • Research Site
      • Anderlecht, Belgio, 1070
        • Ritirato
        • Research Site
      • Bruges, Belgio, 8000
        • Reclutamento
        • Research Site
      • Hasselt, Belgio, 3500
        • Reclutamento
        • Research Site
      • La Louvière, Belgio, 7100
        • Reclutamento
        • Research Site
      • Liège, Belgio, 4000
        • Reclutamento
        • Research Site
      • Barretos, Brasile, 14784-400
        • Reclutamento
        • Research Site
      • Curitiba, Brasile, 80730-150
        • Reclutamento
        • Research Site
      • Florianópolis, Brasile, 88034-000
        • Reclutamento
        • Research Site
      • Ipatinga, Brasile, 35162-189
        • Reclutamento
        • Research Site
      • Natal, Brasile, 59075-740
        • Reclutamento
        • Research Site
      • Porto Alegre, Brasile, 91350-200
        • Reclutamento
        • Research Site
      • Rio de Janeiro, Brasile, 22211-230
        • Reclutamento
        • Research Site
      • Santa Maria, Brasile, 97015-450
        • Reclutamento
        • Research Site
      • São Paulo, Brasile, 01221-020
        • Reclutamento
        • Research Site
      • Taubaté, Brasile, 12030-200
        • Reclutamento
        • Research Site
      • Chicoutimi, Canada, G7H 5H6
        • Reclutamento
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, Canada, VSZ 4E6
        • Reclutamento
        • Research Site
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Ritirato
        • Research Site
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada, A1B 3V6
        • Reclutamento
        • Research Site
    • Ontario
      • London, Ontario, Canada, N6A 4L6
        • Reclutamento
        • Research Site
      • Newmarket, Ontario, Canada, L3Y 2P9
        • Ritirato
        • Research Site
      • Oshawa, Ontario, Canada, L1G 2B9
        • Reclutamento
        • Research Site
      • Toronto, Ontario, Canada, M4N 3M5
        • Ritirato
        • Research Site
    • Quebec
      • Lévis, Quebec, Canada, G6V 0B8
        • Reclutamento
        • Research Site
      • Montreal, Quebec, Canada, H4J 1C5
        • Reclutamento
        • Research Site
      • Montreal, Quebec, Canada, H3T 1E2
        • Reclutamento
        • Research Site
      • Montreal, Quebec, Canada, H3T 1M5
        • Ritirato
        • Research Site
      • Rimouski, Quebec, Canada, G5L 5T1
        • Reclutamento
        • Research Site
      • Trois-Rivières, Quebec, Canada, G8Z 3R9
        • Reclutamento
        • Research Site
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7N 4H4
        • Reclutamento
        • Research Site
      • Beijing, Cina, 100142
        • Reclutamento
        • Research Site
      • Beijing, Cina, 101149
        • Reclutamento
        • Research Site
      • Changchun, Cina, 130000
        • Reclutamento
        • Research Site
      • Changsha, Cina, 410013
        • Reclutamento
        • Research Site
      • Chengdu, Cina, 610000
        • Reclutamento
        • Research Site
      • Chengdu, Cina, 610041
        • Reclutamento
        • Research Site
      • Chongqing, Cina, 400030
        • Reclutamento
        • Research Site
      • Fuzhou, Cina, 350014
        • Reclutamento
        • Research Site
      • Guangzhou, Cina, 510080
        • Reclutamento
        • Research Site
      • Hangzhou, Cina, 310006
        • Reclutamento
        • Research Site
      • Hangzhou, Cina, 310022
        • Reclutamento
        • Research Site
      • Hangzhou, Cina, 310016
        • Reclutamento
        • Research Site
      • Harbin, Cina, 150049
        • Reclutamento
        • Research Site
      • Hefei, Cina, 230601
        • Reclutamento
        • Research Site
      • Hefei, Cina, 230031
        • Ritirato
        • Research Site
      • Jinan, Cina, 250117
        • Reclutamento
        • Research Site
      • Jining, Cina, 272011
        • Ritirato
        • Research Site
      • Kunming, Cina, 650118
        • Reclutamento
        • Research Site
      • Lanzhou, Cina, 730000
        • Reclutamento
        • Research Site
      • Linhai, Cina, 317000
        • Reclutamento
        • Research Site
      • Linyi, Cina, 276001
        • Reclutamento
        • Research Site
      • Nanjing, Cina, 210009
        • Reclutamento
        • Research Site
      • Nanning, Cina, 530021
        • Reclutamento
        • Research Site
      • Nanning, Cina, 530000
        • Reclutamento
        • Research Site
      • Shanghai, Cina, 200032
        • Reclutamento
        • Research Site
      • Shanghai, Cina, 200030
        • Reclutamento
        • Research Site
      • Shanghai, Cina, 200433
        • Reclutamento
        • Research Site
      • Shenyang, Cina, 110022
        • Reclutamento
        • Research Site
      • Taiyuan, Cina, 030000
        • Reclutamento
        • Research Site
      • Tianjin, Cina, 300060
        • Reclutamento
        • Research Site
      • Wenzhou, Cina, 325000
        • Reclutamento
        • Research Site
      • Wuhan, Cina, 430022
        • Reclutamento
        • Research Site
      • Wuhan, Cina, 430030
        • Reclutamento
        • Research Site
      • Wuhan, Cina, 430010
        • Reclutamento
        • Research Site
      • Wuhan, Cina, 430000
        • Reclutamento
        • Research Site
      • Xi'an, Cina, 710061
        • Reclutamento
        • Research Site
      • Yangzhou, Cina, 225001
        • Reclutamento
        • Research Site
      • Zhengzhou, Cina, 450000
        • Reclutamento
        • Research Site
      • Zhengzhou, Cina, 450008
        • Reclutamento
        • Research Site
      • Changwon, Corea del Sud, 51353
        • Reclutamento
        • Research Site
      • Incheon, Corea del Sud, 21565
        • Reclutamento
        • Research Site
      • Seongnam-si, Corea del Sud, 13496
        • Reclutamento
        • Research Site
      • Seoul, Corea del Sud, 03080
        • Reclutamento
        • Research Site
      • Seoul, Corea del Sud, 03722
        • Reclutamento
        • Research Site
      • Seoul, Corea del Sud, 08308
        • Non ancora reclutamento
        • Research Site
      • Seoul, Corea del Sud, 06973
        • Reclutamento
        • Research Site
      • Suwon, Corea del Sud, 16247
        • Reclutamento
        • Research Site
      • Suwon, Corea del Sud, 16499
        • Reclutamento
        • Research Site
      • Berlin, Germania, 10249
        • Non ancora reclutamento
        • Research Site
      • Bonn, Germania, 53113
        • Reclutamento
        • Research Site
      • Cologne, Germania, 50677
        • Reclutamento
        • Research Site
      • Düsseldorf, Germania, 40489
        • Ritirato
        • Research Site
      • Essen, Germania, 45136
        • Reclutamento
        • Research Site
      • Freiburg im Breisgau, Germania, 79106
        • Reclutamento
        • Research Site
      • Gauting, Germania, 82131
        • Reclutamento
        • Research Site
      • Georgsmarienhütte, Germania, 49124
        • Ritirato
        • Research Site
      • Gera, Germania, 07548
        • Ritirato
        • Research Site
      • Gütersloh, Germania, 33332
        • Ritirato
        • Research Site
      • Hamburg, Germania, 20251
        • Reclutamento
        • Research Site
      • Hamburg, Germania, 22087
        • Reclutamento
        • Research Site
      • Heidelberg, Germania, 69126
        • Reclutamento
        • Research Site
      • Kempten, Germania, 87439
        • Sospeso
        • Research Site
      • Kiel, Germania, 24116
        • Non ancora reclutamento
        • Research Site
      • Koblenz, Germania, 56068
        • Sospeso
        • Research Site
      • Ludwigsburg, Germania, 71640
        • Ritirato
        • Research Site
      • München, Germania, 81925
        • Reclutamento
        • Research Site
      • Nuremberg, Germania, 90419
        • Ritirato
        • Research Site
      • Potsdam, Germania, 14467
        • Reclutamento
        • Research Site
      • Ravensburg, Germania, 88212
        • Reclutamento
        • Research Site
      • Bunkyō City, Giappone, 113-8431
        • Reclutamento
        • Research Site
      • Bunkyō City, Giappone, 160-0023
        • Reclutamento
        • Research Site
      • Fukuoka, Giappone, 812-8582
        • Reclutamento
        • Research Site
      • Fukuoka, Giappone, 814-0180
        • Reclutamento
        • Research Site
      • Hakodate-shi, Giappone, 040-8611
        • Reclutamento
        • Research Site
      • Hidaka-shi, Giappone, 350-1298
        • Reclutamento
        • Research Site
      • Hirakata-shi, Giappone, 573-1191
        • Reclutamento
        • Research Site
      • Hirosaki-shi, Giappone, 036-8563
        • Reclutamento
        • Research Site
      • Hiroshima, Giappone, 730-8518
        • Reclutamento
        • Research Site
      • Kanazawa, Giappone, 920-8641
        • Reclutamento
        • Research Site
      • Kashiwa, Giappone, 227-8577
        • Reclutamento
        • Research Site
      • Kawasaki-shi, Giappone, 216-8511
        • Reclutamento
        • Research Site
      • Kumamoto, Giappone, 860-8556
        • Reclutamento
        • Research Site
      • Matsusaka-shi, Giappone, 515-8544
        • Reclutamento
        • Research Site
      • Matsuyama, Giappone, 790-0024
        • Reclutamento
        • Research Site
      • Nagoya, Giappone, 460-0001
        • Reclutamento
        • Research Site
      • Niigata, Giappone, 951-8566
        • Reclutamento
        • Research Site
      • Okayama, Giappone, 700-8558
        • Reclutamento
        • Research Site
      • Osaka, Giappone, 545-8586
        • Ritirato
        • Research Site
      • Osakasayama-shi, Giappone, 589-8511
        • Reclutamento
        • Research Site
      • Sagamihara-shi, Giappone, 252-0375
        • Reclutamento
        • Research Site
      • Sapporo, Giappone, 003-0804
        • Reclutamento
        • Research Site
      • Takaoka-shi, Giappone, 933-8555
        • Reclutamento
        • Research Site
      • Takatsuki-shi, Giappone, 569-8686
        • Reclutamento
        • Research Site
      • Tokushima, Giappone, 770-8503
        • Reclutamento
        • Research Site
      • Tokyo, Giappone, 104-0045
        • Reclutamento
        • Research Site
      • Utsunomiya, Giappone, 320-0834
        • Reclutamento
        • Research Site
      • Yokohama, Giappone, 221-0855
        • Reclutamento
        • Research Site
      • Chennai, India, 600031
        • Reclutamento
        • Research Site
      • Dwārka, India, 110075
        • Reclutamento
        • Research Site
      • Jaipur, India, 302004
        • Reclutamento
        • Research Site
      • Kolkata, India, 700099
        • Reclutamento
        • Research Site
      • Marg Jaipur, India, 302004
        • Ritirato
        • Research Site
      • Nagpur, India, 440001
        • Reclutamento
        • Research Site
      • Nashik, India, 422011
        • Reclutamento
        • Research Site
      • New Delhi, India, 11029
        • Reclutamento
        • Research Site
      • New Delhi, India, 110085
        • Reclutamento
        • Research Site
      • Surat, India, 395002
        • Reclutamento
        • Research Site
      • Thiruvananthapuram, India, 695011
        • Ritirato
        • Research Site
      • Bergamo, Italia, 24125
        • Reclutamento
        • Research Site
      • Genoa, Italia, 16132
        • Reclutamento
        • Research Site
      • Milan, Italia, 20141
        • Reclutamento
        • Research Site
      • Milan, Italia, 20162
        • Reclutamento
        • Research Site
      • Monza, Italia, 20052
        • Reclutamento
        • Research Site
      • Padova, Italia, 35128
        • Reclutamento
        • Research Site
      • Pavia, Italia, 27100
        • Reclutamento
        • Research Site
      • Ravenna, Italia, 48100
        • Reclutamento
        • Research Site
      • Roma, Italia, 00128
        • Reclutamento
        • Research Site
      • Rozzano, Italia, 20089
        • Reclutamento
        • Research Site
      • Olsztyn, Polonia, 10-357
        • Reclutamento
        • Research Site
      • Poznan, Polonia, 60-569
        • Reclutamento
        • Research Site
      • Przemyśl, Polonia, 37-700
        • Reclutamento
        • Research Site
      • Warsaw, Polonia, 02-781
        • Reclutamento
        • Research Site
      • Warsaw, Polonia, 01-138
        • Reclutamento
        • Research Site
      • San Juan, Porto Rico, 00909
        • Reclutamento
        • Research Site
      • Cheltenham, Regno Unito, GL53 7AN
        • Sospeso
        • Research Site
      • Inverness, Regno Unito, IV2 3UJ
        • Sospeso
        • Research Site
      • London, Regno Unito, SW17 0QT
        • Reclutamento
        • Research Site
      • London, Regno Unito, SW10 9NH
        • Reclutamento
        • Research Site
      • London, Regno Unito, SE1 9RT
        • Ritirato
        • Research Site
      • Norwich, Regno Unito, NR4 7UY
        • Reclutamento
        • Research Site
      • Preston, Regno Unito, PR2 9HT
        • Reclutamento
        • Research Site
      • Truro, Regno Unito, TR1 3LJ
        • Reclutamento
        • Research Site
      • Alicante, Spagna, 03010
        • Reclutamento
        • Research Site
      • Barcelona, Spagna, 08036
        • Reclutamento
        • Research Site
      • Barcelona, Spagna, 08003
        • Reclutamento
        • Research Site
      • Barcelona, Spagna, 08041
        • Non ancora reclutamento
        • Research Site
      • Jerez de la Frontera, Spagna, 11407
        • Reclutamento
        • Research Site
      • Reus, Spagna, 43204
        • Reclutamento
        • Research Site
      • Salamanca, Spagna, 37007
        • Ritirato
        • Research Site
    • Alaska
      • Anchorage, Alaska, Stati Uniti, 99508
        • Reclutamento
        • Research Site
    • Arizona
      • Tucson, Arizona, Stati Uniti, 85719
        • Reclutamento
        • Research Site
    • Arkansas
      • Little Rock, Arkansas, Stati Uniti, 72205
        • Reclutamento
        • Research Site
      • Springdale, Arkansas, Stati Uniti, 72762
        • Reclutamento
        • Research Site
    • California
      • Anaheim, California, Stati Uniti, 92801
        • Reclutamento
        • Research Site
      • Beverly Hills, California, Stati Uniti, 90211
        • Reclutamento
        • Research Site
      • Fountain Valley, California, Stati Uniti, 92708
        • Reclutamento
        • Research Site
      • Newport Beach, California, Stati Uniti, 92663
        • Sospeso
        • Research Site
    • Florida
      • Clermont, Florida, Stati Uniti, 34711
        • Reclutamento
        • Research Site
      • Gainesville, Florida, Stati Uniti, 32608
        • Reclutamento
        • Research Site
      • Miami Beach, Florida, Stati Uniti, 33140
        • Reclutamento
        • Research Site
      • Orange City, Florida, Stati Uniti, 32763
        • Reclutamento
        • Research Site
      • Orlando, Florida, Stati Uniti, 32806
        • Reclutamento
        • Research Site
      • Orlando, Florida, Stati Uniti, 32827
        • Ritirato
        • Research Site
      • West Palm Beach, Florida, Stati Uniti, 33401
        • Reclutamento
        • Research Site
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Research Site
      • Atlanta, Georgia, Stati Uniti, 30318
        • Reclutamento
        • Research Site
      • Atlanta, Georgia, Stati Uniti, 30342
        • Ritirato
        • Research Site
      • Atlanta, Georgia, Stati Uniti, 30303
        • Sospeso
        • Research Site
    • Illinois
      • Hinsdale, Illinois, Stati Uniti, 60521
        • Reclutamento
        • Research Site
    • Indiana
      • Noblesville, Indiana, Stati Uniti, 46062
        • Reclutamento
        • Research Site
    • Kentucky
      • Paducah, Kentucky, Stati Uniti, 42003
        • Reclutamento
        • Research Site
    • Maryland
      • Annapolis, Maryland, Stati Uniti, 21401
        • Reclutamento
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Research Site
      • Boston, Massachusetts, Stati Uniti, 02114
        • Reclutamento
        • Research Site
    • Michigan
      • Dearborn, Michigan, Stati Uniti, 48126
        • Reclutamento
        • Research Site
      • Farmington Hills, Michigan, Stati Uniti, 48334
        • Reclutamento
        • Research Site
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Reclutamento
        • Research Site
      • Traverse City, Michigan, Stati Uniti, 49684
        • Ritirato
        • Research Site
    • Mississippi
      • Hattiesburg, Mississippi, Stati Uniti, 39401
        • Reclutamento
        • Research Site
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64132
        • Reclutamento
        • Research Site
    • Montana
      • Bozeman, Montana, Stati Uniti, 59715
        • Ritirato
        • Research Site
    • Nebraska
      • Grand Island, Nebraska, Stati Uniti, 68803
        • Reclutamento
        • Research Site
      • Omaha, Nebraska, Stati Uniti, 68130
        • Reclutamento
        • Research Site
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89102
        • Reclutamento
        • Research Site
      • Reno, Nevada, Stati Uniti, 89502
        • Ritirato
        • Research Site
    • New Jersey
      • Voorhees Township, New Jersey, Stati Uniti, 08043
        • Sospeso
        • Research Site
    • New York
      • Stony Brook, New York, Stati Uniti, 11794
        • Reclutamento
        • Research Site
    • North Carolina
      • Greenville, North Carolina, Stati Uniti, 27834
        • Reclutamento
        • Research Site
      • Salisbury, North Carolina, Stati Uniti, 28144
        • Reclutamento
        • Research Site
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45219
        • Reclutamento
        • Research Site
      • Columbus, Ohio, Stati Uniti, 43210
        • Ritirato
        • Research Site
      • Maumee, Ohio, Stati Uniti, 43537
        • Reclutamento
        • Research Site
      • Toledo, Ohio, Stati Uniti, 43623
        • Reclutamento
        • Research Site
    • Oregon
      • Portland, Oregon, Stati Uniti, 97213
        • Ritirato
        • Research Site
    • South Carolina
      • Greenville, South Carolina, Stati Uniti, 29607
        • Reclutamento
        • Research Site
    • South Dakota
      • Sioux Falls, South Dakota, Stati Uniti, 57105
        • Reclutamento
        • Research Site
    • Tennessee
      • Chattanooga, Tennessee, Stati Uniti, 37404
        • Ritirato
        • Research Site
      • Knoxville, Tennessee, Stati Uniti, 37920
        • Ritirato
        • Research Site
    • Texas
      • Fort Worth, Texas, Stati Uniti, 76104
        • Reclutamento
        • Research Site
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Research Site
      • Houston, Texas, Stati Uniti, 77030
        • Ritirato
        • Research Site
      • Houston, Texas, Stati Uniti, 77090
        • Sospeso
        • Research Site
      • Kingwood, Texas, Stati Uniti, 77339
        • Reclutamento
        • Research Site
      • Odessa, Texas, Stati Uniti, 79761
        • Reclutamento
        • Research Site
    • Virginia
      • Fort Belvoir, Virginia, Stati Uniti, 22060
        • Reclutamento
        • Research Site
      • Leesburg, Virginia, Stati Uniti, 20176
        • Reclutamento
        • Research Site
      • Midlothian, Virginia, Stati Uniti, 23114
        • Reclutamento
        • Research Site
      • Richmond, Virginia, Stati Uniti, 23230
        • Reclutamento
        • Research Site
    • Washington
      • Tacoma, Washington, Stati Uniti, 98405
        • Reclutamento
        • Research Site
      • Vancouver, Washington, Stati Uniti, 98684
        • Reclutamento
        • Research Site
      • Wenatchee, Washington, Stati Uniti, 98801
        • Reclutamento
        • Research Site
    • Wisconsin
      • Appleton, Wisconsin, Stati Uniti, 54911
        • Reclutamento
        • Research Site
      • Bangkok, Tailandia, 10400
        • Reclutamento
        • Research Site
      • Bangkok, Tailandia, 10700
        • Reclutamento
        • Research Site
      • Hat Yai, Tailandia, 90110
        • Reclutamento
        • Research Site
      • Muang, Tailandia, 22000
        • Reclutamento
        • Research Site
      • Mueang, Tailandia, 20000
        • Reclutamento
        • Research Site
      • Mueang, Tailandia, 32000
        • Reclutamento
        • Research Site
      • Changhua, Taiwan, 500
        • Non ancora reclutamento
        • Research Site
      • Kaohsiung City, Taiwan, 80756
        • Reclutamento
        • Research Site
      • New Taipei City, Taiwan, 220
        • Reclutamento
        • Research Site
      • Taichung, Taiwan, 40447
        • Reclutamento
        • Research Site
      • Taichung, Taiwan, 40705
        • Reclutamento
        • Research Site
      • Tainan, Taiwan, 704
        • Reclutamento
        • Research Site
      • Taipei, Taiwan, TAIWAN
        • Reclutamento
        • Research Site
      • Taipei, Taiwan, 10002
        • Reclutamento
        • Research Site
      • Taipei, Taiwan, 112
        • Reclutamento
        • Research Site
      • Taipei, Taiwan, 0116
        • Reclutamento
        • Research Site
      • Taoyuan, Taiwan, 333
        • Reclutamento
        • Research Site
      • Adapazarı, Turchia (Türkiye), 54100
        • Reclutamento
        • Research Site
      • Ankara, Turchia (Türkiye), 6200
        • Reclutamento
        • Research Site
      • Ankara, Turchia (Türkiye), 06560
        • Reclutamento
        • Research Site
      • Antalya, Turchia (Türkiye), 07070
        • Reclutamento
        • Research Site
      • Diyarbakır, Turchia (Türkiye), 21280
        • Reclutamento
        • Research Site
      • Istanbul, Turchia (Türkiye), 34030
        • Reclutamento
        • Research Site
      • Istanbul, Turchia (Türkiye), 34890
        • Reclutamento
        • Research Site
      • Budapest, Ungheria, 1121
        • Reclutamento
        • Research Site
      • Edelény, Ungheria, 3780
        • Non ancora reclutamento
        • Research Site
      • Gyula, Ungheria, 5700
        • Sospeso
        • Research Site
      • Gyöngyös, Ungheria, 3200
        • Ritirato
        • Research Site
      • Gyöngyös - Mátraháza, Ungheria, 3200
        • Reclutamento
        • Research Site
      • Győr, Ungheria, 9024
        • Reclutamento
        • Research Site
      • Kecskemét, Ungheria, 6000
        • Reclutamento
        • Research Site
      • Salgótarján, Ungheria, 3100
        • Ritirato
        • Research Site
      • Szekszárd, Ungheria, 7100
        • Reclutamento
        • Research Site
      • Szolnok, Ungheria, 5000
        • Ritirato
        • Research Site
      • Székesfehérvár, Ungheria, 8000
        • Ritirato
        • Research Site
      • Törökbálint, Ungheria, 2045
        • Reclutamento
        • Research Site
      • Da Nang, Vietnam, 550000
        • Reclutamento
        • Research Site
      • Hanoi, Vietnam, 100000
        • Reclutamento
        • Research Site
      • Ho Chi Minh City, Vietnam, 700000
        • Reclutamento
        • Research Site
      • Ho Chi Minh City, Vietnam, 700000
        • Ritirato
        • Research Site
      • Huế, Vietnam, 530000
        • Ritirato
        • Research Site
      • Hà Nội, Vietnam, 100000
        • Reclutamento
        • Research Site
      • Vinh, Vietnam, 460000
        • Ritirato
        • Research Site
      • Vĩnh Yên, Vietnam, 280000
        • Reclutamento
        • Research Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Histologically or cytologically documented non-squamous NSCLC.
  • Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.
  • Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.
  • Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.
  • Known tumour PD-L1 expression status defined as TC ≥ 50%
  • At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline
  • ECOG performance status of 0 or 1
  • Adequate bone marrow reserve and organ function

Exclusion Criteria:

  • Prior systemic therapy for advanced/metastatic NSCLC.
  • Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.
  • History of another primary malignancy within 3 years
  • Active or prior documented autoimmune or inflammatory disorders (with exceptions)
  • Any evidence of severe or uncontrolled disease that makes it undesirable for the participant to participate in the study or that would jeopardies compliance with the protocol.
  • Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.
  • History of any ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, has current or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  • Has significant pulmonary function compromise, as determined by the investigator
  • Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.
  • History of leptomeningeal carcinomatosis
  • Known clinically significant corneal disease
  • Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled
  • History of active primary immunodeficiency

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig

Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Datopotamab Deruxtecan IV (intravenous)

Altri nomi:
  • Dato-DXd

Rilvegostomig IV (intravenous)

Altri nomi:
  • AZD2936
Sperimentale: Arm 2: Rilvegostomig Monotherapy

Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Rilvegostomig IV (intravenous)

Altri nomi:
  • AZD2936
Comparatore attivo: Arm 3: Pembrolizumab Monotherapy

Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Pembrolizumab IV (intravenous)

Altri nomi:
  • KEYTRUDA

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-Free Survival (PFS) in TROP2 biomarker positive participants.
Lasso di tempo: Approximately 4 years

PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population:

• TROP2 biomarker positive population

The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis.

Approximately 4 years
Overall Survival (OS) in TROP2 biomarker positive participants.
Lasso di tempo: Approximately 6 years

OS is defined as the time from randomisation until the date of death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population:

• TROP2 biomarker positive population The measure of interest is the HR of OS.

Approximately 6 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-Free Survival (PFS) in the FAS population.
Lasso di tempo: Approximately 4 years

PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population:

• FAS population

The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis.

Approximately 4 years
Overall Survival (OS) in the FAS population.
Lasso di tempo: Approximately 6 years

OS is defined as the time from randomisation until the date of death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population:

• FAS population The measure of interest is the HR of OS.

Approximately 6 years
Assessment of Objective Response Rate (ORR) by BICR in TROP2 biomarker positive and FAS populations
Lasso di tempo: Approximately 4 years

ORR is defined as the proportion of participants who have a CR or PR, as determined by BICR per RECIST 1.1.

The analyses will include all randomised participants, as randomised, with measurable disease at baseline, in the following populations:

  • TROP2 biomarker positive population
  • FAS population Data obtained from randomisation up until progression, or the last evaluable assessment in the absence of progression, will be included in the assessment of ORR, regardless of whether the participant withdraws from therapy. Participants who go off treatment without a response or progression, receive a subsequent therapy, and then respond will not be included as responders in the ORR.

The measure of interest is the difference of the ORR. ORR by investigator will be reported as a sensitivity analysis.

Approximately 4 years
Assessment of Duration of Response (DoR) by BICR in TROP2 biomarker positive and FAS populations
Lasso di tempo: Approximately 4 years

DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR or death due to any cause.

The analyses will include all randomised participants who have a response, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following populations:

  • TROP2 biomarker positive population
  • FAS population The measure of interest is the median of DoR. DoR by investigator will be reported as a sensitivity analysis.
Approximately 4 years
Participant-reported lung cancer symptoms of NSCLC and participant-reported GHS/QOL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab.
Lasso di tempo: Approximately 6 years

Time to deterioration in: pulmonary symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ, in overall lung cancer symptoms as measured by the NSCLC-SAQ, and in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172.

Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:

  • TROP2 biomarker positive population
  • FAS population The measure of interest is the HR of time to deterioration in pulmonary symptoms, HR of time to deterioration in overall lung cancer symptoms, and HR of time to deterioration in GHS/QoL.
Approximately 6 years
Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab.
Lasso di tempo: Approximately 6 years

Time to deterioration in physical functioning as measured by PROMIS Physical Function short form 8c.

Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:

  • TROP2 biomarker positive population
  • FAS population The measure of interest is the HR of time to deterioration in physical functioning.
Approximately 6 years
Pharmacokinetics (PK)
Lasso di tempo: Approximately 6 years

Concentration of rilvegostomig, Dato-DXd, total anti TROP2 antibody, and MAAA 1181a (payload deruxtecan) in plasma or serum and PK parameters (peak and trough concentrations).

Approximately 6 years
Immunogenicity
Lasso di tempo: Approximately 6 years

Presence of ADA for Dato-DXd and rilvegostomig (confirmatory results, titres and neutralising antibodies for confirmed positive samples).

Approximately 6 years
Second Progression-Free Survival (PFS2).
Lasso di tempo: Approximately 6 years

PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death. Progression event includes radiological (RECIST 1.1) or clinical disease progression.

The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard practice.

The analyses will include all randomised participants, as randomised, regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits, in the following populations:

  • TROP2 biomarker positive population
  • FAS population The measure of interest is the HR of PFS2.
Approximately 6 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety of Dato-DXd in combination with rilvegostomig and rilvegostomig monotherapy as compared with pembrolizumab.
Lasso di tempo: Approximately 6 years

Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0).

Approximately 6 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Suresh S. Ramalingam, MD, Emory University, Atlanta, Georgia, United States of America.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 aprile 2024

Completamento primario (Stimato)

28 dicembre 2029

Completamento dello studio (Stimato)

28 dicembre 2029

Date di iscrizione allo studio

Primo inviato

5 aprile 2024

Primo inviato che soddisfa i criteri di controllo qualità

5 aprile 2024

Primo Inserito (Effettivo)

10 aprile 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

27 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Periodo di condivisione IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.

For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Criteri di accesso alla condivisione IPD

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool .

Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi